PPA
TARO

Parametric Portfolio Associates’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Parametric Portfolio Associates’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.96M Sell
45,261
-3,598
-7% -$168K ﹤0.01% 2429
2021
Q4 		$2.45M Sell
48,859
-13,826
-22% -$775K ﹤0.01% 2318
2021
Q3 		$3.99M Buy
62,685
+2,140
+4% +$148K ﹤0.01% 1990
2021
Q2 		$4.36M Buy
60,545
+12,700
+27% +$933K ﹤0.01% 1942
2021
Q1 		$3.53M Buy
47,845
+11,767
+33% +$893K ﹤0.01% 2405
2020
Q4 		$2.65M Buy
36,078
+21,283
+144% +$1.37M ﹤0.01% 2483
2020
Q3 		$812K Sell
14,795
-25,561
-63% -$1.59M ﹤0.01% 3043
2020
Q2 		$2.68M Buy
40,356
+1,115
+3% +$74.8K ﹤0.01% 2319
2020
Q1 		$2.4M Sell
39,241
-8,967
-19% -$664K ﹤0.01% 2263
2019
Q4 		$4.24M Sell
48,208
-264
-0.5% -$22.3K ﹤0.01% 2179
2019
Q3 		$3.66M Buy
48,472
+12,505
+35% +$1.01M ﹤0.01% 2251
2019
Q2 		$3.07M Buy
35,967
+7,793
+28% +$771K ﹤0.01% 2364
2019
Q1 		$3.04M Buy
28,174
+2,834
+11% +$282K ﹤0.01% 2366
2018
Q4 		$2.15M Sell
25,340
-18,366
-42% -$1.77M ﹤0.01% 2542
2018
Q3 		$4.3M Sell
43,706
-739
-2% -$80K ﹤0.01% 2145
2018
Q2 		$5.14M Sell
44,445
-2,016
-4% -$221K ﹤0.01% 1942
2018
Q1 		$4.59M Sell
46,461
-34,015
-42% -$3.45M ﹤0.01% 1978
2017
Q4 		$8.43M Sell
80,476
-13,503
-14% -$1.48M 0.01% 1459
2017
Q3 		$10.6M Sell
93,979
-10,839
-10% -$1.18M 0.01% 1204
2017
Q2 		$11.7M Buy
104,818
+1,708
+2% +$193K 0.01% 1055
2017
Q1 		$12M Buy
103,110
+13,408
+15% +$1.48M 0.02% 988
2016
Q4 		$9.44M Buy
89,702
+75,670
+539% +$7.93M 0.01% 1082
2016
Q3 		$1.55M Sell
14,032
-5,542
-28% -$734K ﹤0.01% 2520
2016
Q2 		$2.85M Buy
19,574
+7,004
+56% +$993K ﹤0.01% 2045
2016
Q1 		$1.8M Buy
12,570
+6,499
+107% +$923K ﹤0.01% 2485
2015
Q4 		$938K Buy
+6,071
New +$886K ﹤0.01% 2831

Other funds holding TARO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Parametric Portfolio Associates's TARO Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Taro Pharmaceutical Industries Ltd. (TARO) stake by 7.4% in Q1 2022, selling an estimated $168K and leaving 45,261 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2429.

Parametric Portfolio Associates first reported a position in TARO in Q4 2015 and has held it in 26 quarters since. The position peaked at $12M in Q1 2017. 69 funds tracked by Wall St. Rank hold TARO as of Q1 2022.

  • Parametric Portfolio Associates held 45,261 shares of Taro Pharmaceutical Industries Ltd. worth $1.96M as of Q1 2022.
  • Parametric Portfolio Associates sold 3,598 Taro Pharmaceutical Industries Ltd. shares in Q1 2022, an estimated $168K.
  • Taro Pharmaceutical Industries Ltd. made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2429 holding.
  • Parametric Portfolio Associates first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2015 and has held it in 26 quarters since.
  • Parametric Portfolio Associates's Taro Pharmaceutical Industries Ltd. position peaked at $12M in Q1 2017.
  • 69 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.